

### Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended): In a therapeutic composition comprising a bactericidal/permeability-increasing protein product and a stabilizing polyoxypropylene-polyoxyethylene block copolymer (poloxamer) surfactant, the improved composition comprising a bactericidal-activity-enhancing poloxamer surfactant **and EDTA**.

Claim 2 (Cancelled).

Claim 3: The improved composition of claim 1 wherein the bactericidal-activity-enhancing poloxamer surfactant is selected from the group consisting of poloxamer 333, poloxamer 334, poloxamer 335, and poloxamer 403.

Claim 4 (Cancelled).

Claim 9 (currently amended): A composition for inhibiting bacterial and fungal growth comprising a BPI protein product, **and** a bacterial and fungal growth-inhibiting enhancing poloxamer surfactant **and EDTA**.

Claim 11 (original): The composition of claim 9 wherein the bacterial and fungal growth-inhibiting enhancing poloxamer surfactant is selected from the group consisting of poloxamer 333, poloxamer 334, poloxamer 335, and poloxamer 403.